{"id":"sea-cd70","_chembl":null,"_fixedAt":"2026-03-30T11:30:18.765732","_dailymed":null,"_scrapedAt":"2026-03-28T04:11:21.767Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:53:50.775594+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_fixedFields":["pubmed(1)"],"trialDetails":[{"nctId":"NCT04227847","phase":"PHASE1","title":"A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies","status":"RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2020-08-07","conditions":"Myelodysplastic Syndrome, Acute Myeloid Leukemia","enrollment":178}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"recentPublications":[{"date":"2025 Dec 4","pmid":"41344992","title":"TNF-α and IFN-γ differentially regulate AML cell susceptibility to CD70-antibody-mediated cytotoxicity.","journal":"Journal for immunotherapy of cancer"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"SEA-CD70","genericName":"sea-cd70","companyName":"Pfizer Inc.","companyId":"pfizer","modality":"","firstApprovalDate":"","aiSummary":"","enrichmentLevel":5,"visitCount":8,"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:53:50.775594+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}